Your session is about to expire
← Back to Search
Monoclonal Antibodies
Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema (CONGO Trial)
Phase 1 & 2
Waitlist Available
Research Sponsored by AsclepiX Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 0 to week 48
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new medicine called AXT107, which is injected into the eye to help patients with Diabetic Macular Edema (DME). The goal is to see if it can reduce swelling and improve vision in these patients.
Eligible Conditions
- Diabetic Macular Edema
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 0 to week 48
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 0 to week 48
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Safety as Assessed by Incidence of Adverse Events (AEs)
Secondary study objectives
Efficacy as Assessed by Central Retinal Thickness (CST)
Diabetic Retinopathy
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: Mid DoseExperimental Treatment1 Intervention
AXT107 0.25 mg/eye
Group II: Low DoseExperimental Treatment1 Intervention
AXT107 0.1 mg/eye
Group III: High DoseExperimental Treatment1 Intervention
AXT107 0.5 mg/eye
Find a Location
Who is running the clinical trial?
AsclepiX Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
18 Total Patients Enrolled
Amir Shojaei, PhDStudy DirectorAsclepix Therapeutics
1 Previous Clinical Trials
3 Total Patients Enrolled